Aged ≥ 18 years at the time of signing the informed consent form
Histologically or cytologically confirmed early-stage T1-3 N0 NSCLC, or patients with multiple primary lesions or solitary pulmonary parenchymal recurrence
Confirmed presence of EGFR-sensitive mutations by genetic testing, including but not limited to Exon 19 deletion, L858R, G719X, L861Q, S768I, and their compound mutations
ECOG performance status score of 0-2
Deemed medically inoperable or refuse surgery after multidisciplinary evaluation
Pulmonary lesions suitable for ablation or radiotherapy (either modality)
Adequate major organ function
You may not be if
Known severe allergic reaction (NCI-CTCAE v5.0 grade ≥ 3) to any monoclonal antibody or any excipient of the study drug
Known contraindications to ablation or radiotherapy
Failure to meet the minimum requirements for target coverage and dose constraints to organs at risk in the SABR treatment plan
Active infection requiring systemic anti-infective therapy within 14 days prior to the first dose
Patients with hepatitis B (hepatitis B surface antigen \[HBsAg\] positive and detectable HBV-DNA indicating viral replication); hepatitis C (hepatitis C virus \[HCV\] antibody positive and detectable HCV-RNA indicating viral replication)
Receipt of curative-intent radiotherapy within 3 months prior to the first dose
Major surgery within 28 days prior to the first dose (major surgery in this study is defined as any procedure requiring at least 3 weeks of recovery before the study treatment can be administered)
Concurrent participation in another clinical study, or receipt of intervention in any other clinical trial (including drugs and devices) within 3 months or 5 half-lives prior to screening, whichever is longer
Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study
